Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 2
3(100.0%)
3Total
Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT02559778Phase 2Recruiting

Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

Role: collaborator

NCT04301843Phase 2Recruiting

Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma

Role: collaborator

NCT02679144Phase 2Recruiting

Neuroblastoma Maintenance Therapy Trial

Role: collaborator

All 3 trials loaded